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Introduction {#jah31251-sec-0004}
============

Acute heart failure, which includes a variety of cardiac conditions such as cardiogenic shock, acute decompensation of chronic heart failure, right ventricular failure, and acute pulmonary edema (APE), accounts for an increasing number of deaths and hospital admissions.[1](#jah31251-bib-0001){ref-type="ref"}, [2](#jah31251-bib-0002){ref-type="ref"}, [3](#jah31251-bib-0003){ref-type="ref"}, [4](#jah31251-bib-0004){ref-type="ref"}, [5](#jah31251-bib-0005){ref-type="ref"} Although these presentations have their own profile, reports generally pool data from the different subsets and outcomes are presented as from a single entity.[1](#jah31251-bib-0001){ref-type="ref"}, [2](#jah31251-bib-0002){ref-type="ref"}, [3](#jah31251-bib-0003){ref-type="ref"}, [5](#jah31251-bib-0005){ref-type="ref"}, [6](#jah31251-bib-0006){ref-type="ref"} APE, however, may be considered a distinct condition because it develops abruptly, most often within the first hour from symptom onset, and it is often triggered by elements different from those causing a gradual decompensation of chronic heart failure.[1](#jah31251-bib-0001){ref-type="ref"}, [7](#jah31251-bib-0007){ref-type="ref"}, [8](#jah31251-bib-0008){ref-type="ref"}, [9](#jah31251-bib-0009){ref-type="ref"}, [10](#jah31251-bib-0010){ref-type="ref"} Hence, it is suspected that mechanisms of APE may vary from those of decompensated heart failure.[1](#jah31251-bib-0001){ref-type="ref"}, [10](#jah31251-bib-0010){ref-type="ref"}

Several recent studies have reported on the 1‐year prognosis of patients with acute heart failure[4](#jah31251-bib-0004){ref-type="ref"}, [11](#jah31251-bib-0011){ref-type="ref"}, [12](#jah31251-bib-0012){ref-type="ref"}, [13](#jah31251-bib-0013){ref-type="ref"}, [14](#jah31251-bib-0014){ref-type="ref"}, [15](#jah31251-bib-0015){ref-type="ref"}, [16](#jah31251-bib-0016){ref-type="ref"} and 3 have analyzed longer follow‐up,[15](#jah31251-bib-0015){ref-type="ref"}, [16](#jah31251-bib-0016){ref-type="ref"}, [17](#jah31251-bib-0017){ref-type="ref"} one of them with decompensated heart failure and pulmonary edema.[17](#jah31251-bib-0017){ref-type="ref"} In contrast, long‐term follow‐up in patients with well‐defined APE has been limited to 1 year and has been described in only 2 old reports with a reduced number of patients.[7](#jah31251-bib-0007){ref-type="ref"}, [18](#jah31251-bib-0018){ref-type="ref"} Moreover, causes of death in the follow‐up were not investigated.

Thus, in the present study, we analyzed the in‐hospital and long‐term follow‐up events in patients with APE. We also analyzed the causes of death, the prognostic predictors, and the possible differences between patients with and patients without CAD as the main underlying heart disease.

Methods {#jah31251-sec-0005}
=======

Patients {#jah31251-sec-0006}
--------

From January 2000 to December 2010, 806 consecutive patients with APE admitted to our acute cardiac care unit were included. APE was defined as orthopnea of ≤6 hours with bilateral rales, hypoxemia (arterial oxygen saturation \<90%), and radiographic evidence of alveolar and/or interstitial pulmonary edema. Oxygen saturation was assessed on admission and blood pressure, by cuff, and heart rate were measured at first medical attention. Also, a chest X‐ray and a standard 12‐lead electrocardiogram (ECG) were performed on hospital arrival. Serial blood samples for myocardial necrosis markers (creatine kinase MB \[CK‐MB\] and troponin I) were drawn every 4 to 6 hours during at least the first 24 hours. In view of the frequent presence of renal insufficiency in these patients, however, myocardial necrosis was assessed by levels of CK‐MB. Initial treatment included oxygen by mask, intravenous morphine sulphate, intravenous infusion of nitroglycerin, and intravenous furosemide. Sodium nitroprusside was added whenever needed, whereas hypotension was initially treated with dobutamine and/or noradrenaline. Patients with persistent respiratory insufficiency underwent noninvasive ventilatory support, whereas oral intubation and mechanical ventilation were instituted in cases of refractory hypoventilation. Angiotensin‐converting enzyme (ACE) inhibitors or angiotensin receptors antagonists and beta‐blockers were added in the subacute phase of the disease. These drugs along with diuretics were the main line of therapy for heart failure at hospital discharge. In recent years, aldosterone antagonists were also recommended. Additional medications were added according to the underlying heart disease. Also, coronary revascularization procedures, surgical treatment of valvular heart disease, and follow‐up management were dictated by the attending physicians that were largely within the recommendations of appropriate international guidelines.

Echocardiographic Study and Coronary Angiography {#jah31251-sec-0007}
------------------------------------------------

A two‐dimensional echocardiogram Doppler (Vivid 3 or Vivid i with harmonic imaging; General Electric, Fairfield, CT) was performed within 6 hours from admission. Left ventricular end‐diastolic and end‐systolic diameters were measured, and ejection fraction was calculated by the Simpson method; thickness of septal and posterior walls was measured in the long parasternal views. The presence of valvular disease was also investigated and the existence of mitral regurgitation was assessed by a semiquantitative approach by Doppler flow mapping (color). It was judged to be mild, moderate, or severe when the regurgitant jet occupied 5% to 19%, 20% to 39%, or ≥40% of the left atrial area, respectively. To assess diastolic function, diastolic transmitral flow velocities were recorded in the standard apical 4‐chamber view with the sample volume positioned at the mitral leaflet tips. The ratio between peak velocities of the E and A waves and the deceleration time were evaluated. The flow at the pulmonary veins was also analyzed, and diastolic inflow was categorized as normal, impaired relaxation, pseudonormalization, or restrictive patterns.

Coronary angiography was intended to be performed in most patients and was interpreted by 2 observers who visually evaluated by consensus the number of main coronary vessels with ≥70% stenosis. The protocol complied with the Declaration of Helsinki and was approved by the hospital ethics committee, and informed consent was obtained from patients before entering the study.

### Underlying heart disease {#jah31251-sec-0008}

Two cardiac conditions were recognized: CAD and non‐CAD. Diagnosis of CAD was based on ≥1 of the following criteria: (1) previous myocardial infarction (pathological Q waves in ≥2 contiguous leads, enzyme rise, or a fixed perfusion defect in myocardial scintigraphic studies); (2) acute coronary syndromes: acute myocardial infarction with increased levels of CK‐MB mass \>10 μg/L (upper normal limit: 6 μg/L) with or without chest pain or ECG changes, or unstable angina, also with or without chest pain but with transient ECG changes and CKMB mass ≤10 μg/L; or (3) coronary stenosis ≥70% in ≥1 major epicardial vessel. The non‐CAD group included patients with a primary moderate‐severe valvular heart disease, those with dilated (left ventricular end‐diastolic diameter ≥65 mm) or hypertrophic (wall thickness ≥15 mm) cardiomyopathy and those with no apparent heart disease. Patients with myocardial infarction and valvular heart disease, however, were categorized as CAD, whereas those with severe valvular heart disease (severe aortic stenosis, mitral stenosis, or aortic regurgitation) and small myocardial infarction (CK‐MB \<20 μg/L) were classified as non‐CAD.

Statistical Analysis {#jah31251-sec-0009}
--------------------

We compared clinical, electrocardiographic, and echocardiographic and clinical outcome between CAD and non‐CAD patients. We also compared the profile of hospital survivors and nonsurvivors and that of long‐term follow‐up survivors and nonsurvivors. We used the Student *t* test for comparison of 2 continuous variables with normal distribution, the Mann--Whitney *U* test for variables with abnormal distribution, and the chi‐square or the Fisher exact test to compare categorical variables. A multivariable logistic regression analysis examined the predictive value of variables associated with in‐hospital mortality in a univariate analysis, whereas a Cox regression analysis was used for predictors of overall mortality. Long‐term survival was estimated by the Kaplan‐Meier method. The analysis was performed with SPSS software (version 15.0; SPSS, Inc., Chicago, IL), data expressed as mean±SD, and differences considered significant at *P*\<0.05.

Results {#jah31251-sec-0010}
=======

There were 638 patients with CAD and 168 without, of whom 111 had valvular heart disease, 18 a cardiomyopathy, and 39 no apparent heart disease. Moderate‐to‐severe mitral insufficiency, aortic stenosis, and mitral stenosis were judged to be the main valvular disorders in 68, 26, and 17 non‐CAD patients, respectively.

Demographic, Echocardiographic, and Angiographic Data {#jah31251-sec-0011}
-----------------------------------------------------

In most patients, APE was a de novo presentation since 85% of CAD and 84% of non‐CAD cases had no previous episodes. CAD patients were older (73±10 vs 67±13 years; *P*\<0.001) and had a higher rate of diabetes (50% vs 35%; *P*=0.001) and peripheral vascular disease (30% vs 14%; *P*\<0.001) than non‐CAD patients, but showed a lower incidence of chronic atrial fibrillation (15% vs 30%; *P*\<0.001). They also presented a lower ejection fraction (40.7±12.4% vs 50.2±17.0%; *P*\<0.001). Coronary angiography was performed in 506 patients (63%), 69% from the CAD group, and 43% from the non‐CAD group. Significant coronary disease was present in 94% and 32%, respectively, with a predominance of multivessel disease in the former (80%).

In‐Hospital Outcome {#jah31251-sec-0012}
-------------------

In‐hospital mortality occurred in 222 patients (27.5%) and tended to be lower in the CAD (169, 26.5%) than in the non‐CAD group (53; 31.5%; *P*=0.169; Figure [1](#jah31251-fig-0001){ref-type="fig"}). The cause of death was identified in 221 patients and was strictly cardiac in 110 cases (50%), mostly cardiogenic shock or recurrence of APE, whereas in 95 (42.8%) it was associated with complications of the pulmonary edema or a transiently impaired hemodynamic condition. The proportion of cardiac deaths in CAD and non‐CAD patients was similar (49.4% vs 38.5%; *P*=0.200). Nonsurvivors were older than survivors in the 2 groups and had a lower admission blood pressure and lower heart rate. They also had greater impairment of left ventricular diastolic function. Ejection fraction was also lower in nonsurvivors than in survivors in the CAD group, but not in the non‐CAD group where it was higher in nonsurvivors (Table [1](#jah31251-tbl-0001){ref-type="table-wrap"}). In both groups, nonsurvivors were less frequently treated with ACE inhibitors, mostly because they had continued with nitroglycerin infusion, and were more frequently intubated or treated with dobutamine. Recurrence of APE was more often observed in nonsurvivors of the CAD group and in 46 patients (41.1%) it was associated with in‐hospital angina or myocardial infarction. Moreover, the incidence of in‐hospital myocardial infarction or reinfarction was also higher in nonsurvivors than in survivors (Table [2](#jah31251-tbl-0002){ref-type="table-wrap"}). Of the 113 CAD patients with either in‐hospital angina, myocardial infarction, or recurrent APE, nonrevascularized patients showed a strong trend toward a higher mortality than the revascularized ones (31 of 52 \[59.6%\] vs 25 of 61 \[41%\]; *P*=0.060).

![Among patients with APE, those with CAD presented a higher follow‐up and total mortality than those with non‐CAD, whereas in‐hospital mortality was similar. APE indicates acute pulmonary edema; CAD, coronary artery disease.](JAH3-5-e002581-g001){#jah31251-fig-0001}

###### 

Clinical, Angiographic and Echocardiographic Characteristics of Patients With APE

                                                     In‐Hospital Course (n=806)   Follow‐up (n=574)                                                                                                     
  -------------------------------------------------- ---------------------------- ------------------- ------- ----------- ----------- --------- ----------- ----------- ------- ----------- ----------- ---------
  Age, y                                             65.1±13.4                    72.3±9.4            0.001   72.0±9.9    74.0±8.0    0.021     63.4±13.4   68.0±13.0   0.071   68.9±10.3   74.2±9.1    \<0.001
  Female                                             38%                          53%                 0.076   35%         40%         0.256     39%         37%         0.858   30%         38%         0.073
  Hypertension                                       71%                          62%                 0.241   75%         76%         0.782     71%         72%         0.885   77%         75%         0.910
  Diabetes mellitus                                  33%                          40%                 0.406   50%         50%         0.910     24%         49%         0.005   49%         51%         0.584
  Active smoking                                     33%                          11%                 0.017   24%         27%         0.684     38%         24%         0.042   27%         22%         0.524
  Chronic obstructive pulmonary disease              29%                          43%                 0.060   31%         35%         0.333     25%         35%         0.257   31%         31%         0.962
  Previous cerebrovascular accident                  15%                          15%                 0.958   14%         18%         0.165     11%         21%         0.151   10%         16%         0.055
  Peripheral vascular disease                        14%                          15%                 0.839   30%         30%         0.873     6%          28%         0.001   21%         36%         0.001
  Chronic renal failure                              17%                          25%                 0.248   25%         22%         0.487     17%         16%         0.957   21%         28%         0.067
  Old myocardial infarction                          8%                           9%                  0.705   36%         35%         0.784     7%          14%         0.216   31%         39%         0.086
  Chronic atrial fibrillation                        27%                          36%                 0.241   15%         17%         0.432     26%         28%         0.859   11%         18%         0.038
  Previous heart failure                             37%                          40%                 0.782   20%         24%         0.365     36%         40%         0.714   19%         21%         0.534
  Previous APE                                       13%                          23%                 0.115   15%         15%         0.847     13%         14%         0.823   10%         19%         0.009
  Angina during APE                                  18%                          17%                 0.840   64%         65%         0.719     28%         16%         0.180   63%         64%         0.765
  Admission Killip Class IV                          6%                           8%                  0.748   5%          16%         \<0.001   6%          2%          0.649   6%          5%          0.736
  In‐hospital APE                                    29%                          48%                 0.026   23%         33%         0.029     33%         27%         0.499   18%         28%         0.038
  Creatinine, mg/dL                                  1.4±0.4                      1.8±1.6             0.044   1.7±1.3     1.9±1.3     0.110     1.3±0.8     1.7±0.9     0.057   1.5±1.1     2.0±1.4     0.001
  CKMB, μg/L                                         6±8                          6±7                 0.641   86±159      127±190     0.006     7±10        5±4         0.257   90±167      83±154      0.642
  Admission SBP, mm Hg (n=742)                       156±52                       136±40              0.018   154±43      130±42      \<0.001   148±50      170±53      0.031   152±45      155±42      0.355
  Admission DBP, mm Hg (n=742)                       87±29                        72±21               0.001   86±24       76±23       \<0.001   81±26       97±31       0.009   86±25       85±23       0.677
  Admission HR, beats/min (n=742)                    113±32                       103±28              0.059   109±26      102±23      0.005     113±32      113±33      0.977   110±24      109±26      0.836
  Hemoglobin, g/dL                                   12.7±2.4                     11.2±2.2            0.001   12.6±2.3    12.3±2.3    0.271     13.1±2.3    12.0±2.5    0.823   13.0±2.5    12.2±2.1    0.003
  Left bundle branch block                           30%                          43%                 0.101   26%         27%         0.833     28%         35%         0.423   23%         28%         0.234
  Ejection fraction, %                               48.4±16.5                    54.4±17.4           0.039   41.5±12.1   38.5±13.2   0.008     49.7±17.2   46.2±15.3   0.276   42.1±11.9   41.0±12.2   0.322
  LVEDD, mm                                          56.1±9.3                     52.6±10.2           0.047   52.6±7.2    51.0±7.1    0.053     56.0±8.9    56.4±10.3   0.874   52.5±7.2    52.7±7.3    0.745
  LVESD, mm                                          40.6±10.5                    35.5±11.2           0.019   39.6±8.6    38.4±8.0    0.267     40.1±10.3   41.9±11.0   0.492   39.4±8.5    39.7±8.8    0.810
  Septal thickness, mm                               13.2±3.4                     12.6±2.4            0.255   12.6±2.7    12.5±2.7    0.591     12.8±2.9    13.7±4.1    0.185   12.3±2.4    12.8±2.8    0.041
  Posterior wall thickness, mm                       12.2±2.0                     11.9±2.0            0.336   11.7±2.2    11.5±2.1    0.361     12.2±2.1    12.2±2.3    0.950   11.5±2.1    11.9±2.3    0.040
  Diastolic function                                 (n=45)                       (n=22)                      (n=265)     (n=73)                (n=29)      (n=18)              (n=97)      (n=168)     
  Normal                                             2%                           0%                  0.059   2%          0%          0.027     3%          0%          0.190   0%          2%          0.001
  Reduced distensibility                             31%                          5%                          38%         40%                   21%         44%                 34%         54%         
  Pseudonormal pattern                               24%                          55%                         28%         34%                   31%         11%                 31%         26%         
  Restrictive pattern                                42%                          41%                         24%         17%                   45%         33%                 35%         17%         
  Moderate‐severe aortic stenosis                    15%                          25%                 0.346   6%          11%         0.047     18%         9%          0.198   4%          8%          0.176
  Moderate‐severe aortic insufficiency               17%                          21%                 0.568   2%          4%          0.114     22%         9%          0.114   3%          2%          0.700
  Moderate‐severe mitral stenosis                    10%                          11%                 0.801   0.5%        0.6%        0.920     13%         7%          0.372   0.5%        0.4%        0.946
  Mitral insufficiency                                                                                                                                                                                  
  Mild                                               31%                          26%                 0.380   39%         25%         \<0.001   31%         33%         0.714   41%         38%         0.897
  Moderate‐severe                                    42%                          40%                 29%     46%         43%         40%       34%         35%                                         
  Coronary angiography, vessels with ≥70% stenosis                                                            (n=334)     (n=103)     0.206                                     (n=159)     (n=175)     0.172
  0                                                                                                           7%          3%                                                    9%          4%          
  1                                                                                                           16%         17%                                                   17%         16%         
  2                                                                                                           24%         17%                                                   26%         22%         
  3                                                                                                           40%         44%                                                   35%         45%         
  Left main ≥50%                                                                                              13%         19%                                                   13%         13%         

Comparison between survivors and nonsurvivors in the CAD and non‐CAD groups during the in‐hospital course and the follow‐up (%, mean±SD). APE indicates acute pulmonary edema; CAD, coronary artery disease; DBP, diastolic blood pressure; HR, heart rate; LVEDD, left ventricular end‐diastolic diameter; LVESD, left ventricular end‐systolic diameter; SBP, systolic blood pressure.

###### 

Hospital and Follow‐up Management and Events in Patients With APE

                            In‐Hospital Course (n=806)   Follow‐Up (n=574)                                                                         
  ------------------------- ---------------------------- ------------------- --------- ------ ------ --------- ------ ------ ------- ------ ------ ---------
  Hospital treatment                                                                                                                               
  Beta‐blockers             46%                          52%                 0.205     65%    48%    0.001     39%    58%    0.045   67%    64%    0.487
  Nitrates                  96%                          94%                 0.710     96%    89%    \<0.001   94%    98%    0.411   95%    96%    0.615
  ACE inhibitors            71%                          45%                 0.001     95%    62%    \<0.001   75%    65%    0.257   93%    97%    0.092
  Diuretics                 100%                         100%                1.0       99%    100%   0.297     100%   100%   1.0     99%    100%   0.381
  Aspirin                   11%                          13%                 0.723     99%    99%    0.367     8%     16%    0.193   97%    99%    0.109
  Dihydroperidines          7%                           2%                  0.175     38%    31%    0.078     8%     5%     0.453   49%    31%    \<0.001
  Dobutamine                24%                          49%                 0.001     18%    59%    \<0.001   24%    26%    0.812   22%    15%    0.054
  Noradrenaline             17%                          46%                 \<0.001   17%    53%    \<0.001   14%    24%    0.233   18%    17%    0.794
  Endotracheal intubation   20%                          47%                 \<0.001   16%    54%    \<0.001   18%    23%    0.500   17%    15%    0.695
  CPAP                      29%                          39%                 0.201     24%    37%    0.002     33%    21%    0.177   31%    19%    0.004
  Thrombolytics             0%                           0%                            6%     9%     0.222     0%     0%             5%     8%     0.268
  Primary PCI               0%                           0%                            7%     13%    0.075     0%     0%             11%    6%     0.053
  Interventions                                                              0.296                   0.091                   0.008                 \<0.001
  Late PCI                  4%                           0%                            24%    18%              0%     0%             27%    22%    
  CABG                      0%                           0%                            7%     4%               6%     0%             14%    4%     
  Valvular surgery          23%                          23%                           3%     7%               33%    11%            20%    2%     
  Hospital events                                                                                                                                  
  Angina                    2%                           9%                  0.074     10%    18%    0.020     0%     0%             6%     14%    0.009
  Myocardial infarction     0%                           0%                            1.5%   13%    \<0.001   0%     0%             1%     2%     0.593
  Recurrent APE             6%                           16%                 0.086     10%    32%    \<0.001   5%     10%    0.304   6%     14%    0.024
  Follow‐up treatment                                                                                                                              
  Beta‐blockers                                                                                                50%    59%    0.384   70%    74%    0.329
  Nitrates                                                                                                     3%     10%    0.121   30%    18%    0.003
  ACE inhibitors                                                                                               66%    71%    0.586   73%    78%    0.168
  Diuretics                                                                                                    61%    8%     0.467   61%    57%    0.359
  Aldosterone antagonists                                                                                      20%    2%     0.307   19%    9%     0.002
  Aspirin                                                                                                      24%    0%     0.561   71%    86%    \<0.001
  Dihydroperidines                                                                                             3%     2%     0.896   16%    7%     0.001
  Calcium antagonists                                                                                          14%    27%    0.103   23%    14%    0.016
  Statins                                                                                                      49%    27%    0.024   73%    68%    0.232
  Oral anticoagulants                                                                                          66%    41%    0.013   29%    23%    0.126
  Interventions                                                                                                              0.090                 0.024
  PCI                                                                                                          2.8%   7%             5.4%   1.5%   
  CABG                                                                                                         0%     1%             5.4%   2.2%   
  Valvular surgery                                                                                             8.3%   0%             3.2%   0%     

Comparison between survivors and nonsurvivors in the CAD and non‐CAD groups during the in‐hospital course and the follow‐up (%, mean±SD). ACE indicates angiotensin‐converting enzyme; APE, acute pulmonary edema; CABG, coronary artery bypass surgery; CPAP, continuous positive airway pressure, noninvasive ventilation; CVA cerebrovascular accident; PCI, percutaneous coronary intervention.

A multivariable analysis revealed that advanced age, admission systolic blood pressure, recurrence of APE, and need for inotropics or endotracheal intubation were the most significant independent markers of hospital mortality (Table [3](#jah31251-tbl-0003){ref-type="table-wrap"}).

###### 

Multivariable Predictors of In‐Hospital and Overall Mortality in Patients With APE

                                                  OR      95% CI           *P* Value
  ----------------------------------------------- ------- ---------------- -----------
  In‐hospital mortality                                                    
  Age (per year)                                  1.062   1.031 to 1.092   \<0.001
  Endotracheal intubation                         2.733   1.573 to 4.772   \<0.001
  Dobutamine                                      2.910   1.642 to 5.711   \<0.001
  Recurrent APE                                   2.414   1.362 to 4.273   0.003
  Admission systolic blood pressure (per mm Hg)   0.993   0.984 to 0.988   0.008
  CAD                                             1.842   1.102 to 3.081   0.020
  Overall mortality                                                        
  Age (per year)                                  1.028   1.021 to 1.073   \<0.001
  Peripheral vascular disease                     1.672   1.683 to 4.532   \<0.001
  Peak CKMB, per μg/L                             1.001   1.000 to 1.002   0.001
  Coronary revascularization---valvular surgery   0.883   0.785 to 0.988   0.001
  Diabetes                                        1.353   1.059 to 1.719   0.015
  Mitral insufficiency                            1.164   1.034 to 1.303   0.015
  Chronic obstructive pulmonary disease           1.392   1.066 to 1.807   0.015
  Creatinine, per mg/dL                           1.113   1.020 to 1.217   0.016
  Aortic stenosis                                 1.201   1.026 to 1.391   0.022
  Dobutamine                                      1.741   1.269 to 2.389   0.031
  Female sex                                      1.323   1.008 to 1.737   0.043

Main hospital and overall mortality predictors using a single model with multiple predictors are listed with the corresponding units in continuous variables or as the presence of categorical variables. CAD indicates coronary artery disease; CK‐MB, creatine kinase MB; OR, odds ratio.

Follow‐up Events {#jah31251-sec-0013}
----------------

Of the 584 hospital survivors, there were 10 with a missing follow‐up (1.2%), all from the CAD group, and median follow‐up for the 258 total survivors was 45 months (range, 10--40). There were 316 deaths that resulted in a follow‐up mortality of 55.1% (316 of 574) that was higher in CAD than in non‐CAD patients (273 of 459 \[59.5%\] vs 43 of 115 \[37.4%\]; *P*\<0.001; Table [2](#jah31251-tbl-0002){ref-type="table-wrap"}; Figure [1](#jah31251-fig-0001){ref-type="fig"}). In the 2 groups, nonsurvivors were older than survivors and showed a higher rate of peripheral vascular disease, a higher creatinine, and lower hemoglobin levels. Nonsurvivors underwent less frequently coronary revascularization procedures or valve replacement than survivors, although this was often attributable to notable comorbidities (Table [2](#jah31251-tbl-0002){ref-type="table-wrap"}). Among survivors, hospital readmissions for nonfatal heart failure were higher in CAD than in non‐CAD patients (17.3% vs 7.6%; *P*=0.009). Cause of death in the follow‐up could be determined in 226 of 316 patients (72%), 192 of 273 with CAD (70%), and 34 of 43 with non‐CAD (79%). Death was of cardiac origin in 85 of 226 patients (38%), 76 of 192 of those with CAD (40%), and 9 of 34 of those with non‐CAD (27%; *P*=0.180).

Overall Mortality {#jah31251-sec-0014}
-----------------

Total mortality was high (538 of 796; 67.6%) and was higher in CAD (442 of 628; 70.4%) than in non‐CAD patients (96 of 168 \[57.1%\]; *P*\<0.002; Figures [1](#jah31251-fig-0001){ref-type="fig"}, [2](#jah31251-fig-0002){ref-type="fig"} through [3](#jah31251-fig-0003){ref-type="fig"}), and this difference remained apparent in subsets with different age (Figure [2](#jah31251-fig-0002){ref-type="fig"}). Cardiac mortality among patients with known cause of death tended to be higher in CAD (158 of 361 \[43.8%\] vs 29 of 87 \[33.3%\]; *P*=0.090). A Cox regression analysis disclosed that advanced age, peripheral vascular disease, and peak CK‐MB during hospitalization index were the main independent predictors of mortality, whereas coronary revascularization or valvular surgery were significantly protective (Table [3](#jah31251-tbl-0003){ref-type="table-wrap"}). Most of these interventions were performed during hospitalization index (294 of 307; 96%), and patients who did not undergo these procedures were older (73±10 vs 70±10 years; *P*\<0.001) and more often female (42% vs 29%; *P*\<0.001), and had a higher rate of peripheral vascular disease (32% vs 22%; *P*=0.004) and previous renal insufficiency (25% vs 19%; *P*=0.057) than those not intervened. Ejection fraction, however, was similar in survivors and nonsurvivors in the 2 groups.

![Total mortality in patients with APE and CAD was higher than in those with non‐CAD across the groups of different age (*P*=0.018) (numbers within brackets indicate CAD and non‐CAD cases). APE indicates acute pulmonary edema; CAD, coronary artery disease.](JAH3-5-e002581-g002){#jah31251-fig-0002}

![Kaplan--Meier survival curve showing a strong trend toward higher mortality in patients with APE and CAD that was mainly apparent during the follow‐up. APE indicates acute pulmonary edema; CAD, coronary artery disease.](JAH3-5-e002581-g003){#jah31251-fig-0003}

Discussion {#jah31251-sec-0015}
==========

The principal findings of our study were: (1) a high hospital mortality that was similar in CAD and non‐CAD patients and that was mostly secondary to a cardiac cause or to complications derived from APE; (2) a higher 4‐year mortality and hospital readmission rate for nonfatal heart failure in CAD than in non‐CAD patients; and (3) the existence of different predictors of hospital and overall mortality.

In‐Hospital Outcome {#jah31251-sec-0016}
-------------------

Several investigators have reported on the in‐hospital mortality in patients with acute heart failure, which is an ample concept that includes acute decompensation of chronic heart failure, cardiogenic shock with or without pulmonary edema, right ventricular failure, and APE.[3](#jah31251-bib-0003){ref-type="ref"}, [6](#jah31251-bib-0006){ref-type="ref"}, [14](#jah31251-bib-0014){ref-type="ref"}, [19](#jah31251-bib-0019){ref-type="ref"}, [20](#jah31251-bib-0020){ref-type="ref"}, [21](#jah31251-bib-0021){ref-type="ref"} In these studies, mortality has varied from 6.4% to 17.2% and they have shown advanced age,[6](#jah31251-bib-0006){ref-type="ref"}, [14](#jah31251-bib-0014){ref-type="ref"}, [19](#jah31251-bib-0019){ref-type="ref"}, [21](#jah31251-bib-0021){ref-type="ref"} severe left ventricular dysfunction,[14](#jah31251-bib-0014){ref-type="ref"} acute coronary syndromes,[14](#jah31251-bib-0014){ref-type="ref"} admission blood pressure,[6](#jah31251-bib-0006){ref-type="ref"}, [19](#jah31251-bib-0019){ref-type="ref"}, [21](#jah31251-bib-0021){ref-type="ref"} renal failure,[6](#jah31251-bib-0006){ref-type="ref"}, [19](#jah31251-bib-0019){ref-type="ref"}, [21](#jah31251-bib-0021){ref-type="ref"} need for inotropics,[19](#jah31251-bib-0019){ref-type="ref"} and anemia[19](#jah31251-bib-0019){ref-type="ref"} as principal predictors.

In patients with APE, in‐hospital mortality seems comparable to patients with acute heart failure ranging also from 7.4% to 17%,[7](#jah31251-bib-0007){ref-type="ref"}, [10](#jah31251-bib-0010){ref-type="ref"}, [18](#jah31251-bib-0018){ref-type="ref"}, [22](#jah31251-bib-0022){ref-type="ref"}, [23](#jah31251-bib-0023){ref-type="ref"} although in small and earlier reports,[7](#jah31251-bib-0007){ref-type="ref"}, [18](#jah31251-bib-0018){ref-type="ref"} mortality was higher (12% and 17%) than in larger, more recent studies (7.4%--9.6%).[10](#jah31251-bib-0010){ref-type="ref"}, [22](#jah31251-bib-0022){ref-type="ref"}, [23](#jah31251-bib-0023){ref-type="ref"} Nevertheless, in patients admitted to critical care areas---such as in our study---hospital mortality is higher (32%), at least in the only reported series that involved 199 patients.[24](#jah31251-bib-0024){ref-type="ref"} In our work, hospital mortality was somewhat lower (25%), but it was higher than in patients not admitted to critical care areas,[7](#jah31251-bib-0007){ref-type="ref"}, [10](#jah31251-bib-0010){ref-type="ref"}, [18](#jah31251-bib-0018){ref-type="ref"}, [22](#jah31251-bib-0022){ref-type="ref"}, [23](#jah31251-bib-0023){ref-type="ref"} likely because of the more severe respiratory and/or hemodynamic condition, as indicated by the high need for endotracheal intubation or inotropic agents (26% and 29%), respectively. Another possible explanation was the high proportion of de novo cases of APE (\>80%), a fact that has also been associated with higher hospital mortality.[20](#jah31251-bib-0020){ref-type="ref"} In comparison with existing series,[7](#jah31251-bib-0007){ref-type="ref"}, [10](#jah31251-bib-0010){ref-type="ref"}, [18](#jah31251-bib-0018){ref-type="ref"}, [22](#jah31251-bib-0022){ref-type="ref"}, [23](#jah31251-bib-0023){ref-type="ref"} we found similar major in‐hospital mortality markers, such as age, admission blood pressure, and the need for endotracheal intubation or inotropic agents. Nevertheless, we observed additional strong predictors not previously reported, such as moderate‐to‐severe mitral regurgitation and hospital recurrence of APE. The former was present in more than one third of patients and in a similar proportion of those with or without CAD, whereas the latter occurred more frequently in CAD patients and could be partly attributed to myocardial ischemia because in 46% it was associated with recurrence of angina or myocardial infarction.

Total Mortality {#jah31251-sec-0017}
---------------

Most series that have analyzed total mortality in patients with acute heart failure have reported only a 1‐year follow‐up with mortality rates ranging from 17.4% to 34%[5](#jah31251-bib-0005){ref-type="ref"}, [11](#jah31251-bib-0011){ref-type="ref"}, [12](#jah31251-bib-0012){ref-type="ref"}, [13](#jah31251-bib-0013){ref-type="ref"}, [14](#jah31251-bib-0014){ref-type="ref"} and higher in patients admitted to a critical care area (46.5%).[4](#jah31251-bib-0004){ref-type="ref"} Predictors of 1‐year mortality appeared also to be age,[12](#jah31251-bib-0012){ref-type="ref"}, [13](#jah31251-bib-0013){ref-type="ref"}, [14](#jah31251-bib-0014){ref-type="ref"}, [15](#jah31251-bib-0015){ref-type="ref"} admission blood pressure,[13](#jah31251-bib-0013){ref-type="ref"}, [15](#jah31251-bib-0015){ref-type="ref"} anemia,[13](#jah31251-bib-0013){ref-type="ref"} renal failure,[12](#jah31251-bib-0012){ref-type="ref"}, [13](#jah31251-bib-0013){ref-type="ref"}, [15](#jah31251-bib-0015){ref-type="ref"} left ventricular dysfunction, and acute coronary syndromes.[14](#jah31251-bib-0014){ref-type="ref"} There are few studies (3), however, that have analyzed a longer follow‐up in patients with acutely decompensated heart failure,[15](#jah31251-bib-0015){ref-type="ref"}, [16](#jah31251-bib-0016){ref-type="ref"}, [17](#jah31251-bib-0017){ref-type="ref"} with mortality rates of 60.3%[15](#jah31251-bib-0015){ref-type="ref"} and 71%,[16](#jah31251-bib-0016){ref-type="ref"} with similar main predictors than in the 1‐year follow‐up series.[15](#jah31251-bib-0015){ref-type="ref"}

In contrast to acute heart failure, only 2 studies have investigated the 1‐year mortality in patients with APE[7](#jah31251-bib-0007){ref-type="ref"}, [18](#jah31251-bib-0018){ref-type="ref"} and none has analyzed a longer follow‐up. The 2 studies were carried out nearly 2 decades ago and included 86[18](#jah31251-bib-0018){ref-type="ref"} and 150 patients[7](#jah31251-bib-0007){ref-type="ref"} with a mortality of 51.2% and 40%, respectively. In the present work, which is mostly an investigation of a de novo APE, the 4‐year mortality was 62%, and was higher in CAD than in non‐CAD patients. Moreover, death was more frequently of noncardiac origin, particularly in non‐CAD patients. Most significant independent markers were age, peripheral vascular disease, and peak CK‐MB during hospitalization index.

Hospital readmission rate for APE or acute decompensated heart failure was also higher in CAD than in non‐CAD patients. As expected, revascularized CAD patients and those with non‐CAD who had valvular replacement showed a lower hospital and long‐term mortality or recurrence of heart failure than those without these procedures. Indeed, the Cox regression analysis showed that practice of coronary revascularization or valvular surgery was significantly protective. Revascularization or valve replacement procedures, however, were less frequently performed in elderly patients mainly because of relevant comorbidities. Noteworthy, the more severe prognosis of CAD patients is likely multifactorial because they were older and had a higher rate of peripheral vascular disease, diabetes, and multivessel coronary disease conditions that portend~~s~~ a more severe arteriosclerotic profile. It is unclear why ejection fraction was not a marker of mortality, but, in part, this may relate to the rather high incidence of noncardiac deaths.

Strengths and Limitations {#jah31251-sec-0018}
-------------------------

Relevant findings of our study and not previously reported are the 4‐year prognosis of patients with APE and the comparison of outcomes between patients with and without CAD. Also of importance is the fact that identification of CAD patients was based not only on clinical grounds, but also on coronary angiography data available in 69% of them, but also in 43% of those with non‐CAD. This is in contrast to most existing series of APE[7](#jah31251-bib-0007){ref-type="ref"}, [10](#jah31251-bib-0010){ref-type="ref"}, [23](#jah31251-bib-0023){ref-type="ref"} or acute heart failure,[1](#jah31251-bib-0001){ref-type="ref"}, [2](#jah31251-bib-0002){ref-type="ref"}, [3](#jah31251-bib-0003){ref-type="ref"}, [4](#jah31251-bib-0004){ref-type="ref"}, [5](#jah31251-bib-0005){ref-type="ref"}, [13](#jah31251-bib-0013){ref-type="ref"} where angiographic data are not provided. Of interest is the documentation of significant coronary artery stenosis in 32% of non‐CAD patients who underwent cardiac catheterization, pointing to the concomitant presence of CAD in patients with the primary diagnosis of valvular heart disease. In addition, all our patients had an echocardiogram during the first few hours from hospital admission to evaluate the underlying heart disease. Follow‐up was long and thorough given that only 1.7% of patients were lost, and in 73% the cause of death could be identified. As limitations, we recognized that our results may not be applicable to patients with previous admission with APE because in 85% it was a first event, or to those admitted to a regular ward rather than to a critical care area. Another drawback is the fact that only a minority of patients were treated with aldosterone antagonists. This, in part, may be explained by the years in which the study was carried out and also by the not infrequent presence of moderate renal failure.

Implications {#jah31251-sec-0019}
------------

Our results indicate that APE---at least in patients with a first episode admitted to an acute cardiac care unit---is associated with a high hospital and 4‐year mortality, particularly in those with CAD. In the latter subset, the role of advanced arteriosclerosis in their poor prognosis is underscored. On the other hand, coronary revascularization and valvular surgery significantly reduced overall mortality. Thus, identifying high‐risk patients for in‐hospital and long‐term mortality, in part, through the predictors herein described---which do not necessarily implicate the systolic function---we may speculate that a more aggressive interventional program might improve survival in high‐risk patients despite the frequent comorbidities. In keeping with this and in view of the fact that recurrence of in‐hospital APE---one of the markers of in‐hospital mortality---was often caused by recurrent symptomatic or silent myocardial ischemia, an increase in the frequency of coronary angiography and early revascularization might have improved their outcome.
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